0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease

      , , ,

      Parkinsonism & Related Disorders

      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Most treatment advances in PD have been based on restoring dopaminergic input. The development of levodopa was the first breakthrough and, since then, other compounds have been developed. Each antiparkinsonian medication has its own profile of efficacy and adverse effects, and these can largely be explained by their modes of action. As patients receive a number of different compounds, physicians should be aware of the differences of agents and understand how these differences may relate to clinical practice. This article reviews the three main classes of dopaminergic PD therapy (levodopa, monoamine oxidase inhibitors and dopamine agonists).

          Related collections

          Author and article information

          Journal
          Parkinsonism & Related Disorders
          Parkinsonism & Related Disorders
          Elsevier BV
          13538020
          December 2007
          December 2007
          : 13
          : 8
          : 466-479
          Article
          10.1016/j.parkreldis.2007.06.015
          17919963
          © 2007

          Comments

          Comment on this article